This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (withdrawn) A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof:



(I)

wherein

Q is $(CH_2)_m(CH(R^1))_n(CH_2)_p$;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl;

provided that the compound is not:

2-[4-[5-(2,4-dichlorophenyl)furan-2-yl]-1,3-thiazol-2-yl]acetic acid.

2. (withdrawn) A compound according to claim 1 wherein Q is CH_2.

3. (withdrawn) A compound according to claim 1 wherein R^2 is hydrogen or halogen.

4. (withdrawn) A compound according to claim 1 wherein R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxyl or C_{1-6} alkoxy, CF_3, OR^6, $NHCOR^8$ or $CONHR^9$, wherein at least one of R^3, R^4 and R^5 is other than hydrogen.

5. (withdrawn) A compound according to claim 4 wherein one of R^3 and R^4 is $NHCOR^8$ and the other is hydrogen or halogen, and R^5 is hydrogen.

6. (withdrawn) A compound according to claim 1 wherein R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by phenyl, wherein the phenyl is optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo; or a 5- to 10-membered mono- or bicyclic heteroaryl group containing one to three heteroatoms selected from O, N and S, which heteroaryl group is optionally substituted by C_{1-6} alkyl, C_{1-6} alkoxy or halogen.

7. (withdrawn) A compound according to claim 6 wherein R^8 is C_{1-6} alkyl or C_{2-6} alkenyl, either of which is optionally substituted by phenyl, wherein the phenyl is optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6}

alkyl, methylenedioxo and $NR^{10}R^{11}$; phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo; or a 5- to 10-membered mono- or bicyclic heteroaryl group containing one to three heteroatoms selected from O, N and S, which heteroaryl group is optionally substituted by C_{1-6} alkyl, C_{1-6} alkoxy or halogen.

8. (withdrawn) A compound according to claim 1 selected from

2-[4-[5-(2,3-Dichlorophenyl)furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[4-(2-Benzyloxyethylcarbamoyl)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(2,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(4-bromo)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(2,4-dichloro)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(3,5-bistrifluoromethyl)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-(3-phenylacryloylamino)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-(2-methyl-3-phenylacryloylamino)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(benzothiophene-2-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(6-chloro-4H-chromene-3-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-chlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-bromophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3,4-methylenedioxophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-chlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(5-bromopyrindine-3-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-trifluoromethyl-4-fluorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-cyanophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-methoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(furan-2-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid, and

2-[4-[5-[2-Chloro-4-[3-(4-methoxy)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

or a pharmaceutically acceptable salt or prodrug thereof.

9. (withdrawn) A compound according to claim 1 selected from:

2-[4-[5-[2-Chloro-4-[(2,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(4-bromo)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(2,4-dichloro)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(3,5-ditrifluoromethyl)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-(3-phenylacryloylamino)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(benzothiophene-2-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(6-chloro-4H-chromene-3-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-methoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid, and

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

or a pharmaceutically acceptable salt or prodrug thereof.

10. (canceled)

11. (withdrawn) A process for the preparation of a compound according to claim 1 which comprises:

reacting a compound of formula (II):



(II)

with a compound of formula (III):



(III)

wherein R^A is H, C_{1-6} alkyl or a protecting group; optionally followed by deprotection of the group OR^A, to give the corresponding carboxylic acid.

12. (withdrawn) A process for the preparation of a compound according to claim 1 wherein one or more of R^3, R^4 and R^5 is $NHCOR^8$ which comprises:

reacting a compound of formula (VIII):



(VIII)

wherein one or more of R^3, R^4 and R^5 is NH_2, and R^A is H, C_{1-6} alkyl or a protecting group, with a compound of formula (IX):



(IX)

in an amide bond formation reaction.

13. (withdrawn) A pharmaceutical composition comprising a-compound according to formula (I) or a pharmaceutically acceptable salt or prodrug thereof:



(I)

wherein

Q is $(CH_2)_m(CH(R^1))_n(CH_2)_p$;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl;

together with a pharmaceutically acceptable carrier or excipient.

14-17. (canceled)

18. (withdrawn) A compound of formula (II):



(II)

wherein

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl.

19. (withdrawn) A compound of formula (X):



(X)

wherein

Q is $(CH_2)_m(CH(R^1))_n(CH_2)_p$;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^A is H, C_{1-6} alkyl, or a protecting group;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl and

heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl;

provided that at least one of R^3, R^4 and R^5 is NO_2.

20. (canceled)

21. (currently amended) A method for the ~~treatment~~ therapeutic therapy of colorectal cancer, prostate cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, pancreatic cancer, renal cancer, gastric cancer, bladder cancer or ovarian cancer comprising administering to a patient suffering ~~from cancer~~ therefrom a pharmaceutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or prodrug thereof:



(I)

wherein

Q is $(CH_2)_m(CH(R^1))_n(CH_2)_p$;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl or C_{3-6} alkynyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, OR^6, CN and methylenedioxo;

R^3, R^4 and R^5 are, independently, hydrogen, halogen, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, CF_3, OR^6, COR^7, $NHCOR^8$, $NHCONHR^8$, $NHSO_2R^8$, $CONHR^9$, CN, SO_2R^8 or $NR^{10}R^{11}$;

R^6 is hydrogen, C_{2-6} alkenyl, C_{3-6} alkynyl, C_{1-6} alkyl optionally substituted by hydroxy or C_{1-6} alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and methylenedioxo;

R^7 is C_{1-6} alkyl, OR^6 or phenyl optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, CN, C_{1-6} alkyl, C_{1-6} alkoxy and $NHCOR^8$;

R^8 is C_{1-6} alkyl, C_{2-6} alkenyl, or C_{1-6} alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$; C_{3-6} cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from NR^{12}, S and O; or aryl or heteroaryl, wherein the aryl and

heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF_3, OCF_3, OR^6, CN, C_{1-6} alkyl, methylenedioxo and $NR^{10}R^{11}$;

R^9 is C_{1-6} alkyl, C_{1-6} alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C_{1-6} alkyl, CF_3, OCF_3, CN, C_{1-6} alkoxy and methylenedioxo;

R^{10} and R^{11} are, independently, hydrogen or C_{1-6} alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR^{12}, O and S; and

R^{12} is hydrogen or C_{1-6} alkyl.

22-27. (canceled)